Table 1 |
||||
|
Demographic, biopsy, and clinical data for 120 patients given salivary gland biopsies for Sjögren's syndrome (SS) |
||||
|
Clinical and laboratory parameters |
FSa = 0 |
0 < FS < 1 |
1 ≤ FS < 2 |
FS ≥ 2 |
|
|
||||
|
No. of patients |
57 |
11 |
15 |
37 |
|
Sex |
9M/48F |
1 M/10 F |
0 M/15 F |
3 M/34 F |
|
Age (years) |
46 ± 12 |
46 ± 11 |
54 ± 14 |
56 ± 13 |
|
Baseline biopsy area (mm2) |
6.1 ± 5.6 |
8.3 ± 2.8 |
8.6 ± 4.3 |
4.7 ± 2.6 |
|
Cumulative area of three biopsies (mm2) |
17.1 ± 15.1 |
21.8 ± 9.3 |
22.6 ± 12.7 |
12.9 ± 6.4 |
|
Findings [No. (%)] |
||||
|
Dry eyes |
49 (86) |
9 (81) |
14 (93) |
33 (89) |
|
Xerostomia |
45 (79) |
7 (63) |
14 (93) |
35 (94) |
|
Positive Schirmer's test |
24 (42) |
4 (36) |
9 (60) |
18 (51) |
|
Reduced salivary flow rate |
30 (53) |
7 (63) |
13 (86) |
34 (91) |
|
Antinuclear antibodies |
29 (51) |
8 (73) |
8 (53) |
31 (83) |
|
Ro/SS-A |
18 (31) |
3 (27) |
6 (40) |
25 (67) |
|
La/SS-B |
3 (5) |
0 |
3 (20) |
10 (27) |
|
Rheumatoid factor |
27 (47) |
5 (45) |
7 (46) |
33 (89) |
|
SS according to AECG criteria [No. (%)] |
7 (12) |
1 (9) |
15 (100) |
34 (92) |
|
SS according to clinical re-evaluation [No. (%)] |
7 (12) |
0 (0) |
8 (53) |
34 (92) |
|
|
||||
|
aThe focus score (FS) is the number of inflammatory infiltrates of at least 50 cells present in 4 mm2 of salivary gland area. AECG, American-European Consensus Group; F, female; M, male; SS-A, anti-Ro60 antibodies; SS-B, anti-La antibodies. |
||||
|
Morbini et al. Arthritis Res Ther 2005 7:R343 doi:10.1186/ar1486 |
||||
